Arrowhead Research must modify study

The Food and Drug Administration asked Arrowhead Research Corp. (Nasdaq: ARWR) to lower the dosage of its hepatitis B treatment ARC-520 in a Phase 2b study. The stock price plunged $2.16 to close at $6.90.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.